Scleroderma Pipeline | 20+ Key Players & 22+ Pipeline Drugs | DelveInsight

DelveInsight's, "Scleroderma Pipeline Insight, 2022," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Scleroderma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Scleroderma Pipeline Insight Report
• DelveInsight's analysis depicts a robust Scleroderma Pipeline with 30+ active players in the domain working on 30+ pipeline therapies.
• Key Scleroderma pipeline therapies such as Lenabasum, EHP 101, FT011, Belumosudil, Guselkumab, ECCS 50, KHK4827, SAR156597, Treprostinil, HZN-825, GS-248, Brentuximab Vedotin, C21, ARG201, Belumosudil, CAM2043, Tofacitinib, Sarilumab, FCX 013, VIB7734, AVID200 and others are under evaluation in different phases of clinical trials for the treatment of Scleroderma.
• Corbus Pharmaceuticals, Emerald Health Pharmaceuticals, Gesynta Pharma, Formation Biologics, Fibrocell Science, CSL Behring, ChemomAb, Luminary Therapeutics, Certa Therapeutics, Kadmon Corporation, Janssen Pharmaceutical, Horizon Therapeutics, Acceleron Pharma, Tvardi Therapeutics, BriaCell Therapeutics, Blade Therapeutics, Biosplice Therapeutics, AnaMar, Immunemed, Viela Bio among several others are key prominent pharma companies working in the domain.
• The Scleroderma Companies and academics are working to assess challenges and seek opportunities that could influence Scleroderma R&D. The therapies under development are focused on novel approaches to treat/improve Scleroderma.

Recent Developmental Activities in the Scleroderma Pipeline
• In January 2021, Timber Pharmaceuticals received Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis.
• CiVi 030 is an intravenous formulation of iloprost, a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc). CiVi 030 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Systemic Sclerosis (SSc).
• In April 2020, Horizon Therapeutics announced that it had acquired Curzion Pharmaceuticals and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825), for the treatment of Systemic Sclerosis.
• FCX-013 is being developed as a disease-modifying, autologous cell-based gene therapy that utilizes lentiviral vectors to deliver functional matrix metalloproteinase 1 genes (MMP-1) to patients with moderate to severe localized Scleroderma.
• The U. S. Food and Drug Administration has granted Orphan Drug designation to FCX-013 for the treatment of localized Scleroderma. In addition, FCX-013 has been granted Rare Pediatric Disease designation and Fast Track designation for the treatment of moderate to severe localized Scleroderma.

Request for Sample to know which pharma company is expected to be at the forefront in the coming years, Scleroderma Emerging Therapies and Forecast @ https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scleroderma Overview

A scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Scleroderma affects women more often than men and most commonly occurs between the ages of 30 and 50. While there is no cure for scleroderma, a variety of treatments can ease symptoms and improve quality of life. There are many different types of scleroderma. In some people, scleroderma affects only the skin. But in many people, scleroderma also harms structures beyond the skin, such as blood vessels, internal organs and the digestive tract (systemic scleroderma). Scleroderma results from an overproduction and accumulation of collagen in body tissues. There are 2 main types of scleroderma: localised scleroderma - just affects the skin and systemic sclerosis - may affect blood circulation and internal organs as well as the skin.

Scleroderma Emerging Drugs

Lenabasum: Corbus Pharmaceuticals

Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models of disease. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells. Lenabasum has demonstrated acceptable safety and tolerability profiles in clinical studies to date. It is currently in Phase III for Systemic scleroderma and is being developed by Corbus Pharmaceuticals.

EHP 101: Emerald Health Pharmaceuticals

EHP-101 is an oral formulation of a new chemical entity derived from synthetic, one of the most abundant molecules found in the plant. The fully synthetic novel molecule formulated in EHP-101 has been rationally designed to enhance the therapeutic benefits by being a dual peroxisome proliferator-activated receptor gamma (PPARγ) and type 2 receptor (CB2) agonist that also activates the hypoxia inducible factor (HIF) pathway. I tis currently in Phase II scleroderma and is being developed by Emerald Health Pharmaceuticals.

Scleroderma Pipeline Therapeutic Analysis

There are approx. 30+ key companies which are developing the therapies for Scleroderma. The companies which have their Scleroderma drug candidates in the most advanced stage, i.e. Preregistration include, Corbus Pharmaceuticals.

Discover more about the disease, treatments, and pipeline therapies, Scleroderma Pipeline Assessment @ https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scleroderma Pipeline Therapeutics Assessment

The Scleroderma Pipeline report proffers an integral view of the Scleroderma emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

Scope of the Scleroderma Pipeline Report
• Coverage: Global
• Key Players: Corbus Pharmaceuticals, Emerald Health Pharmaceuticals, Gesynta Pharma, Formation Biologics, Fibrocell Science, CSL Behring, ChemomAb, Luminary Therapeutics, Certa Therapeutics, Kadmon Corporation, Janssen Pharmaceutical, Horizon Therapeutics, Acceleron Pharma, Tvardi Therapeutics, BriaCell Therapeutics, Blade Therapeutics, Biosplice Therapeutics, AnaMar, Immunemed, Viela Bio among others.
• Key Scleroderma Pipeline Therapies: Lenabasum, EHP 101, FT011, Belumosudil, Guselkumab, ECCS 50, KHK4827, SAR156597, Treprostinil, HZN-825, GS-248, Brentuximab Vedotin, C21, ARG201, Belumosudil, CAM2043, Tofacitinib, Sarilumab, FCX 013, VIB7734, AVID200 and several others.

Table of Content
1. Introduction
2. Executive Summary
3. Scleroderma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Scleroderma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Scleroderma Collaboration Deals
9. Late Stage Products (Phase III)
10. Lenabasum: Corbus Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. EHP 101: Emerald Health Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. CM-101: ChemomAb
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. LMY 920: Luminary Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Scleroderma Key Companies
23. Scleroderma Key Products
24. Scleroderma- Unmet Needs
25. Scleroderma- Market Drivers and Barriers
26. Scleroderma- Future Perspectives and Conclusion
27. Scleroderma Analyst Views
28. Scleroderma Key Companies
29. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Scleroderma drugs?
• How many Scleroderma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scleroderma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Scleroderma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Scleroderma and their status?
• What are the key designations that have been granted to the emerging drugs?

Discover more about the scope of the report, Scleroderma Emerging Therapies, Treatments, and Ongoing Clinical Trials @ https://www.delveinsight.com/report-store/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.